QNGY yields 2702.70% · ABBV yields 3.06%● Live data
📍 QNGY pulled ahead of the other in Year 1
Combined, QNGY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of QNGY + ABBV for your $10,000?
Quanergy Systems, Inc. develops and markets light detection and ranging (LiDAR) solutions for automotive and IoT applications. The company offers M1 LiDAR sensor for mid-long range industrial measurement applications; M1 Edge 2D LiDAR sensor that enables reliable collision avoidance and smart navigation; M8 LiDAR sensor, which provides 3D perception using multiple eye-safe laser beams and time-of-flight measurement technology; MQ-8 LiDAR sensor for flow management applications; M8-Prime 3D LiDAR sensor that provides industry-leading pinpoint accuracy and captures for industrial and mapping applications; S3 solid state LiDAR sensor; QORTEX DTC, a 3D computer perception software; and QORTEX people counter enables the development of accurate and innovative people counting and queue management applications. Its products are used in various applications, such as mapping, security, smart city and smart spaces, industrial automation, and transportation applications. The company was founded in 2012 and is headquartered in Sunnyvale, California. On December 13, 2022, Quanergy Systems, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Full QNGY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.